Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. The index has shown a price loss of -51.12% this year. Over the last six months, there has been a stronger performance of -53.21%. The price of ATXS leaped by -11.90% during the last 30 days period. For the last 5-days stocks have improved 1.86%.
Astria Therapeutics Inc experienced a rather shaky stock market performance. The highest value in the past year was recorded at $12.92 on 09/20/24 and the lowest value was $3.56 on 04/09/25.
52-week price history of ATXS Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Astria Therapeutics Inc’s current trading price is -66.18% away from its 52-week high, while its distance from the 52-week low is 22.93%. The stock’s price range during this period has varied between$3.56 and $12.92. The Astria Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 0.5 million for the day, a figure considerably higher than their average daily volume of 0.46 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Astria Therapeutics Inc (ATXS) has experienced a quarterly decline of -31.18% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 246.62M and boasts a workforce of 78 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 5.99, with a change in price of -4.57. Similarly, Astria Therapeutics Inc recorded 382,343 in trading volume during the last 100 days, posting a change of -51.12%.
ATXS’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for ATXS stands at 0.02. Similarly, the long-term debt-to-equity ratio is also 0.01.
ATXS Stock Stochastic Average
Astria Therapeutics Inc’s raw stochastic average for the past 50 days is presently 26.26%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 38.15%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 24.47% and 18.79%, respectively.
